ResMed Inc. FY 2025 10-K, explained in plain English
Key financials — as reported
| Total revenue | $5.1B |
| Gross margin | 59.4% |
| Operating income | $1.7B |
| Net income | $1.4B |
| Diluted EPS | $9.51 |
| Cash & equivalents | $1.2B |
| Total assets | $8.2B |
| Long-term debt | $658.4M |
Key takeaway
ResMed reported $5.15 billion in revenue and $1.40 billion in net income for fiscal year 2025, with a 59.4% gross margin.
🔒 4 more takeaways in the full analysis
Beneath the surface
Cash of $1.21 billion versus total debt of about $668 million (DebtLongtermAndShorttermCombinedAmount) suggests a net cash position of roughly $541 million, better than the headline long-term debt figure alone implies.
🔒 4 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 8 more findings — plus insider trades, activist stakes, and 8-K events for RMD.
Read the full analysis free Free account · 5 full analyses included · no card required